Management of Non-Small Cell Lung Cancer: Updates from the European Lung Cancer Congress 2022

Sankalp Arora, Palash Asawa, Nilansh Kataria, Lizza E L Hendriks, Aakash P Desai*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

2 Downloads (Pure)

Abstract

The recently concluded European Lung Cancer Congress 2022 (ELCC22) showcased some very exciting data, with more than 200 abstracts presented during the meeting. Through this review, we focus on selected clinically relevant abstracts that in our opinion represent significant updates in the current management of non-small cell lung cancer (NSCLC). Here, we summarize the updates in surgical management, adjuvant therapy and therapy for advanced stage NSCLC and put these advances in context of current clinical standard of care.

Original languageEnglish
Pages (from-to)577-589
Number of pages13
JournalCancer Investigation
Volume40
Issue number7
Early online date29 Jun 2022
DOIs
Publication statusPublished - 9 Aug 2022

Keywords

  • 1ST-LINE TREATMENT
  • CHEMOTHERAPY
  • DOUBLE-BLIND
  • GEFITINIB
  • MULTICENTER
  • MUTATIONS
  • Non-small cell lung cancer
  • OSIMERTINIB
  • PHASE-III
  • SURVIVAL
  • adjuvant
  • advanced
  • metastatic

Cite this